{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:43:19Z","timestamp":1790808199304,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1012134","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000}}],"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI125462"],"award-info":[{"award-number":["R01AI125462"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI132256"],"award-info":[{"award-number":["R01AI132256"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R42-AI122403"],"award-info":[{"award-number":["R42-AI122403"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute of Health","award":["T32-AI070117"],"award-info":[{"award-number":["T32-AI070117"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R25GM104547"],"award-info":[{"award-number":["R25GM104547"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long <jats:italic>in vivo<\/jats:italic> half-life as well as the capacity to induce immune-mediated virus clearance. Their activities can be further enhanced by integration of their variable fragments (Fvs) into bispecific antibodies (bsAbs), affording simultaneous targeting of multiple epitopes to improve potency and breadth and\/or to mitigate against viral escape by a single mutation. Here, we explore a bsAb strategy for generation of pan-ebolavirus and pan-filovirus immunotherapeutics. Filoviruses, including Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV), cause severe hemorrhagic fever. Although there are two FDA-approved mAb therapies for EBOV infection, these do not extend to other filoviruses. Here, we combine Fvs from broad ebolavirus mAbs to generate novel pan-ebolavirus bsAbs that are potently neutralizing, confer protection in mice, and are resistant to viral escape. Moreover, we combine Fvs from pan-ebolavirus mAbs with those of protective MARV mAbs to generate pan-filovirus protective bsAbs. These results provide guidelines for broad antiviral bsAb design and generate new immunotherapeutic candidates.<\/jats:p>","DOI":"10.1371\/journal.ppat.1012134","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T20:20:42Z","timestamp":1712866842000},"page":"e1012134","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies"],"prefix":"10.1371","volume":"20","author":[{"given":"Ariel S.","family":"Wirchnianski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth K.","family":"Nyakatura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Kuehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn A.","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay G. A.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandrew","family":"Dailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna M.","family":"Abelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Z.","family":"Wec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinjoy","family":"Chakraborti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Holtsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shulenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Bornholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Javad","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna N.","family":"Honko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-0015","authenticated-orcid":true,"given":"Jonathan R.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ppat.1012134.ref001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcv.2015.01.014","article-title":"Ebola and Marburg haemorrhagic fever.","volume":"64","author":"V Rougeron","year":"2015","journal-title":"J Clin Virol."},{"issue":"7","key":"ppat.1012134.ref002","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.cell.2015.06.007","article-title":"Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone","volume":"161","author":"DJ Park","year":"2015","journal-title":"Cell"},{"issue":"6","key":"ppat.1012134.ref003","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3201\/eid2206.160021","article-title":"Perspectives on West Africa Ebola Virus Disease Outbreak, 2013\u20132016","volume":"22","author":"JR Spengler","year":"2016","journal-title":"Emerging infectious diseases"},{"issue":"1","key":"ppat.1012134.ref004","first-page":"144","article-title":"Sudan Ebola virus (SUDV) outbreak in Uganda, 2022: lessons learnt and future priorities for sub-Saharan Africa.","volume":"21","author":"G Bwire","year":"2023","journal-title":"BMC Med.PubMed Central PMCID"},{"issue":"15","key":"ppat.1012134.ref005","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection","volume":"375","author":"RT Davey","year":"2016","journal-title":"The New England journal of medicine"},{"key":"ppat.1012134.ref006","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","author":"X Qiu","year":"2014","journal-title":"Nature"},{"issue":"8","key":"ppat.1012134.ref007","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2021.57.8.3280599","article-title":"Atoltivimab\/maftivimab\/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus.","volume":"57","author":"D Saxena","year":"2021","journal-title":"Drugs Today (Barc)."},{"key":"ppat.1012134.ref008","doi-asserted-by":"crossref","first-page":"1083429","DOI":"10.3389\/fphar.2023.1083429","article-title":"Ebanga\u2122: The most recent FDA-approved drug for treating Ebola","volume":"14","author":"E Taki","year":"2023","journal-title":"Front Pharmacol.PubMed Central PMCID"},{"issue":"1","key":"ppat.1012134.ref009","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.","volume":"15","author":"MR Gaudinski","year":"2018","journal-title":"PLoS Med."},{"issue":"12","key":"ppat.1012134.ref010","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"GJ Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"21","key":"ppat.1012134.ref011","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"A Gupta","year":"2021","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ppat.1012134.ref012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates","volume":"25","author":"ZA Bornholdt","year":"2019","journal-title":"Cell host & microbe"},{"issue":"1","key":"ppat.1012134.ref013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.chom.2018.12.004","article-title":"Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.","volume":"25","author":"AZ Wec","year":"2019","journal-title":"Cell host & microbe"},{"issue":"384","key":"ppat.1012134.ref014","article-title":"Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody","volume":"9","author":"CE Mire","year":"2017","journal-title":"Science translational medicine"},{"issue":"7201","key":"ppat.1012134.ref015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"JE Lee","year":"2008","journal-title":"Nature"},{"issue":"6","key":"ppat.1012134.ref016","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fvl.09.56","article-title":"Ebolavirus glycoprotein structure and mechanism of entry","volume":"4","author":"JE Lee","year":"2009","journal-title":"Future virology"},{"issue":"4","key":"ppat.1012134.ref017","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.sbi.2009.05.004","article-title":"Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it","volume":"19","author":"JE Lee","year":"2009","journal-title":"Current opinion in structural biology"},{"issue":"4","key":"ppat.1012134.ref018","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection","volume":"174","author":"EO Saphire","year":"2018","journal-title":"Cell"},{"issue":"7364","key":"ppat.1012134.ref019","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"JE Carette","year":"2011","journal-title":"Nature"},{"key":"ppat.1012134.ref020","article-title":"Ebola virus entry requires the host-programmed recognition of an intracellular receptor2012 2012-04-18 00:00:00.","author":"EH Miller","year":"1947"},{"issue":"39","key":"ppat.1012134.ref021","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1021\/bi300976m","article-title":"Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation","volume":"51","author":"JF Koellhoffer","year":"2012","journal-title":"Biochemistry"},{"issue":"6","key":"ppat.1012134.ref022","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1073\/pnas.96.6.2662","article-title":"Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-\u00c5 resolution","volume":"96","author":"VN Malashkevich","year":"1999","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5","key":"ppat.1012134.ref023","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","article-title":"Structural basis for Marburg virus neutralization by a cross-reactive human antibody","volume":"160","author":"T Hashiguchi","year":"2015","journal-title":"Cell"},{"issue":"4","key":"ppat.1012134.ref024","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/v4040447","article-title":"Structural basis for differential neutralization of ebolaviruses.","volume":"4","author":"S Bale","year":"2012","journal-title":"Viruses."},{"issue":"6","key":"ppat.1012134.ref025","doi-asserted-by":"crossref","first-page":"e1005016","DOI":"10.1371\/journal.ppat.1005016","article-title":"Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.","volume":"11","author":"ML Fusco","year":"2015","journal-title":"PLoS pathogens."},{"issue":"10","key":"ppat.1012134.ref026","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.celrep.2018.08.009","article-title":"Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop","volume":"24","author":"CD Murin","year":"2018","journal-title":"Cell Rep"},{"issue":"6277","key":"ppat.1012134.ref027","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"ZA Bornholdt","year":"2016","journal-title":"Science (New York, NY)."},{"issue":"5","key":"ppat.1012134.ref028","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses","volume":"169","author":"AZ Wec","year":"2017","journal-title":"Cell"},{"issue":"5","key":"ppat.1012134.ref029","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of human antibody-mediated neutralization of Marburg virus","volume":"160","author":"AI Flyak","year":"2015","journal-title":"Cell"},{"issue":"3","key":"ppat.1012134.ref030","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection","volume":"164","author":"AI Flyak","year":"2016","journal-title":"Cell"},{"issue":"2","key":"ppat.1012134.ref031","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus","volume":"24","author":"BM Gunn","year":"2018","journal-title":"Cell host & microbe"},{"key":"ppat.1012134.ref032","article-title":"Bispecific Antibodies for Viral Immunotherapy.","author":"EK Nyakatura","year":"2016","journal-title":"Human vaccines & immunotherapeutics."},{"issue":"16","key":"ppat.1012134.ref033","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1074\/jbc.RA117.001627","article-title":"Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins","volume":"293","author":"EK Nyakatura","year":"2018","journal-title":"J Biol Chem"},{"issue":"13","key":"ppat.1012134.ref034","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.cell.2021.05.001","article-title":"Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever","volume":"184","author":"JM Fels","year":"2021","journal-title":"Cell"},{"key":"ppat.1012134.ref035","doi-asserted-by":"crossref","first-page":"19193","DOI":"10.1038\/srep19193","article-title":"Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.","volume":"6","author":"JC Frei","year":"2016","journal-title":"Scientific reports."},{"issue":"6310","key":"ppat.1012134.ref036","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \"Trojan horse\" bispecific-antibody strategy for broad protection against ebolaviruses.","volume":"354","author":"AZ Wec","year":"2016","journal-title":"Science (New York, NY)."},{"key":"ppat.1012134.ref037","doi-asserted-by":"crossref","first-page":"729851","DOI":"10.3389\/fimmu.2021.729851","article-title":"Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity.","volume":"12","author":"AS Wirchnianski","year":"2021","journal-title":"Front Immunol."},{"issue":"24","key":"ppat.1012134.ref038","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.1128\/JVI.02097-15","article-title":"Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization","volume":"89","author":"M Asokan","year":"2015","journal-title":"Journal of virology"},{"issue":"7859","key":"ppat.1012134.ref039","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41586-021-03461-y","article-title":"Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice","volume":"593","author":"R De Gasparo","year":"2021","journal-title":"Nature"},{"issue":"7","key":"ppat.1012134.ref040","first-page":"1621","article-title":"Engineered Bispecific Antibodies with Exquisite HIV-1-","volume":"165","author":"Y Huang","year":"2016","journal-title":"Neutralizing Activity. Cell"},{"issue":"3","key":"ppat.1012134.ref041","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41590-022-01138-w","article-title":"An engineered bispecific human monoclonal antibody against SARS-CoV-2","volume":"23","author":"Z Li","year":"2022","journal-title":"Nature immunology"},{"issue":"3","key":"ppat.1012134.ref042","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S2666-5247(23)00035-6","article-title":"Solidarity Against Ebola: an update","volume":"4","author":"U. Samarasekera","year":"2023","journal-title":"Lancet Microbe"},{"issue":"11","key":"ppat.1012134.ref043","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nbt1345","article-title":"Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin","volume":"25","author":"C Wu","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"13","key":"ppat.1012134.ref044","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"AF Labrijn","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"ppat.1012134.ref045","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/nprot.2014.169","article-title":"Controlled Fab-arm exchange for the generation of stable bispecific IgG1.","volume":"9","author":"AF Labrijn","year":"2014","journal-title":"Nat Protoc."},{"issue":"262","key":"ppat.1012134.ref046","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009655","article-title":"A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.","volume":"6","author":"A DiGiandomenico","year":"2014","journal-title":"Sci Transl Med."},{"issue":"1","key":"ppat.1012134.ref047","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","article-title":"The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.","volume":"23","author":"LB King","year":"2018","journal-title":"Cell host & microbe"},{"issue":"1\u20132","key":"ppat.1012134.ref048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jim.2007.01.008","article-title":"Antibody internalization studied using a novel IgG binding toxin fusion","volume":"321","author":"Y Mazor","year":"2007","journal-title":"J Immunol Methods"},{"issue":"1","key":"ppat.1012134.ref049","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/JVI.01832-09","article-title":"A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry","volume":"84","author":"AC Wong","year":"2010","journal-title":"Journal of Virology"},{"issue":"18","key":"ppat.1012134.ref050","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00336-20","article-title":"A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition.","volume":"94","author":"RH Bortz","year":"2020","journal-title":"Journal of virology"},{"issue":"Pt 6","key":"ppat.1012134.ref051","article-title":"The role of the Type I interferon response in the resistance of mice to filovirus infection","volume":"82","author":"M. Bray","year":"2001","journal-title":"J Gen Virol"},{"issue":"6359","key":"ppat.1012134.ref052","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"L Xu","year":"2017","journal-title":"Science"},{"issue":"4","key":"ppat.1012134.ref053","doi-asserted-by":"crossref","first-page":"e00801","DOI":"10.1128\/mBio.00801-15","article-title":"Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion.","volume":"6","author":"LM Kleinfelter","year":"2015","journal-title":"mBio."},{"issue":"51","key":"ppat.1012134.ref054","doi-asserted-by":"crossref","first-page":"18420","DOI":"10.1073\/pnas.0507123102","article-title":"An antiviral role for the RNA interference machinery in Caenorhabditis elegans","volume":"102","author":"DH Schott","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"ppat.1012134.ref055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/515386","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"178","author":"M Bray","year":"1998","journal-title":"The Journal of infectious diseases"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1012134","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T17:57:05Z","timestamp":1713895025000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012134"}},"subtitle":[],"editor":[{"given":"Alexander","family":"Bukreyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1012134","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.ppat.1012134","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}